update on momelotinib for myelofibrosis
Published 4 years ago • 200 plays • Length 4:25Download video MP4
Download video MP3
Similar videos
-
1:26
updates on the use of momelotinib for the treatment of mf & clinical trials evaluating this agent
-
3:56
an update on manifest: pelabresib monotherapy or as add-on to ruxolitinib in myelofibrosis
-
1:20
overview & updates on the momentum trial comparing momelotinib and danazol in myelofibrosis
-
3:00
the promise of momelotinib in the treatment of myelofibrosis
-
2:07
analysis of long-term exposure to momelotinib in the phase iii simplfy myelofibrosis trials
-
2:21
clinical updates on the use of momelotinib for mpns
-
1:53
recent updates from the momentum trial and the value of momelotinib for the treatment of mf
-
3:48
efficacy of momelotinib in thrombocytopenic patients with myelofibrosis from momentum
-
4:44
7-year update on a phase ii trial of fixed-duration obinutuzumab, ibrutinib, and venetoclax for cll
-
4:35
updated safety & efficacy data from manifest-2: pelabresib plus ruxolitinib for myelofibrosis
-
1:40
momelotinib for the treatment of myelofibrosis
-
1:15
ongoing trials of ruxolitinib, momelotinib and imetelstat in myelofibrosis
-
2:07
the current research on momelotinib for myelofibrosis
-
1:16
indirect comparison of the safety of momelotinib vs fedratinib in patients with myelofibrosis
-
1:01
latest advances in myelofibrosis treatment
-
1:52
an update on the use of navtemadlin in myelofibrosis
-
4:15
the latest data on momelotinib for mpns
-
2:16
long-term safety of momelotinib for myelofibrosis
-
1:44
an update on imetelstat in r/r myelofibrosis
-
1:01
clinical outcomes for patients with myelofibrosis after transition from ruxolitinib to momelotinib
-
1:45
momelotinib vs soc in patients with mf and anemia: an analysis from the simplify-2 trial